Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZOLJB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Ab85 D265C/H435A ADC A
|
|||||
| Synonyms |
Ab85-D265C/H435A-ADC-A
Click to Show/Hide
|
|||||
| Organization |
Heidelberg Pharma Research GmbH
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Ab85 D265C/H435A
|
Antibody Info | ||||
| Antigen Name |
T-cell surface antigen CD2 (CD2)
|
Antigen Info | ||||
| Payload Name |
Amaninamide (thioether)
|
Payload Info | ||||
| Therapeutic Target |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala-PABC
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the engineered cysteine (THIOMAB).
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.